Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e90f06a6-12b7-4a0e-941a-265d903b6295&Preview=1
Date 7/28/2009
Company Name Cerulean Pharmaceuticals
Mailing Address 161 First Street Cambridge, MA 02142
Company Description Within the field of nanopharmaceuticals, Cerulean Pharma is uniquely focused on a next-generation approach we call Nanobiology. Cerulean’s nanobiology-based drug development is based on a deep understanding of the complex biological microenvironment of human disease combined with engineering therapies on a nanoscale, enabling the creation of breakthrough drugs that optimally target the root causes of disease.
Proceeds Purposes Cerulean intends to use the proceeds from the financing to advance the clinical development of IT-101, a cyclodextrin-based camptothecin nanoparticle recently in-licensed from Calando Pharmaceuticals, Inc., and to accelerate the preclinical development of nanoparticle-based drugs using both Cerulean’s pre-existing nanoparticle-based technology as well as the in-licensed cyclodextrin-based nanoparticle technology.
